SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
HPE amended its cooperation agreement with Elliott Investment Management to constrain board size to 14 directors through the 2027 Annual Meeting, modifying governance and board composition restrictions.
View raw filing on EDGAR →The disclosure reports that the Phase 2/3 POWER1 study of vormatrigine failed to meet its primary success measure in focal onset seizures, though secondary measures were met. The Company is pausing enrollment in the POWER2 study to reassess the program. For a clinical-stage biopharmaceutical company, a failed primary endpoint in a pivotal Phase 2/3 trial represents a material setback to a key development program that would significantly affect investor assessment of the company's pipeline and prospects. This does not fit neatly into the specific event categories (not a restatement, impairment, or litigation), making "other_material" the appropriate classification.
View raw filing on EDGAR →Immuneering announced updated Phase 2a clinical trial data for atebimetinib in pancreatic cancer showing a 17.3-month median overall survival versus 8.5 months for standard of care, along with a 36% overall response rate and 82% disease control rate. While this is a clinical trial update rather than a formal earnings release or other specifically enumerated event type, the positive efficacy and safety data for a lead product candidate in a pivotal development stage would materially affect investor assessment of the company's prospects, particularly given the announced Phase 3 trial initiation expected in mid-2026.
View raw filing on EDGAR →Sable Offshore disclosed a new investor presentation and an updated reserve estimate letter from NSAI (its independent reserve engineer) as of May 31, 2026, along with a scheduled investor conference call. While Item 7.01 is typically used for routine Regulation FD disclosures, the inclusion of updated proved, probable, and possible reserve estimates from the company's independent reserve engineer—a material metric for oil and gas companies—suggests this disclosure carries substantive information that could affect investor assessment. However, the filing does not clearly indicate what specific operational, financial, or reserve changes prompted the update, making it difficult to classify into a more specific event category. The disclosure is material to investors in an energy company but does not fit neatly into the standard taxonomy.
View raw filing on EDGAR →Noble Corp entered into a Third Amendment to its Senior Secured Revolving Credit Agreement on May 29, 2026, increasing total revolving commitments from $550 million to $650 million and extending the maturity from April 2028 to May 2031. This refinancing materially affects the company's liquidity and debt structure.
View raw filing on EDGAR →Noble Corp announced a planned private offering of $500 million in unsecured senior notes due 2034, a material financing event that affects the company's capital structure and liquidity.
View raw filing on EDGAR →Noble Finance II LLC, a wholly-owned subsidiary of Noble Corp, priced an $800 million offering of unsecured senior notes due 2034, upsized from the original $500 million. This is a material debt issuance that affects the company's capital structure and financial obligations, but does not fit neatly into the more specific event categories (it is not M&A, a restatement, auditor change, going concern, impairment, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive equity issuance, or litigation). The debt offering is material to investors as it represents a significant financing event.
View raw filing on EDGAR →D-Wave announced a multi-year gate-model quantum computing roadmap with specific technical milestones through 2032, including targets for logical qubits and error reduction factors. This disclosure of a material strategic initiative and long-term product development plan does not fit neatly into the standard 8-K taxonomy (not earnings, M&A, executive changes, impairments, or litigation), but would affect a reasonable investor's assessment of the company's technical direction and competitive positioning in quantum computing. The roadmap represents a significant strategic commitment that could influence investor expectations about the company's future commercialization prospects.
View raw filing on EDGAR →The Company announced successful placement of its 2026-2027 catastrophe excess of loss reinsurance program for its insurance subsidiary. While this is a material operational event for an insurance company (reinsurance placement is critical to risk management and financial stability), it does not fit neatly into the standard 8-K taxonomy. The disclosure is made under Regulation FD (Item 7.01) rather than a more specific Item, and the event involves securing reinsurance capacity rather than earnings, M&A, executive changes, or other enumerated categories.
View raw filing on EDGAR →Summit Midstream announced an inaugural $35.0 million stock repurchase program on June 1, 2026. While share repurchases can signal management confidence and affect capital allocation, this disclosure does not fit neatly into the standard 8-K taxonomy (not earnings, M&A, executive changes, impairment, covenant breach, or other defined categories). The materiality to investors is moderate—repurchases affect EPS and capital structure—but the event lacks the terminal or crisis-level significance of restatements, going-concern, or bankruptcy filings. Classified as other_material given the $35M authorization and inaugural nature.
View raw filing on EDGAR →The fund disclosed detailed portfolio composition and metrics as of April 30, 2026, including loan commitments ($1,860M), par value ($1,395M), portfolio company metrics (median EBITDA, leverage ratios, yields), recent loan activity, and industry diversification. This comprehensive financial and operational data is material to investors assessing the fund's asset quality, risk profile, and performance.
View raw filing on EDGAR →The fund declared a distribution of $0.22 per share and disclosed NAV information as of April 30, 2026 ($24.78 per Common Share, $716 million aggregate), with a caveat that final results may differ materially. This periodic disclosure is material to investors monitoring the fund's distributions and net asset value.
View raw filing on EDGAR →The fund disclosed detailed portfolio composition and metrics as of April 30, 2026, including loan commitments ($497M), par value ($381M), portfolio company metrics, recent loan activity, industry diversification, a declared distribution of $0.19 per share, and NAV of $24.70 per Common Share ($194 million aggregate).
View raw filing on EDGAR →The disclosure announces a resubmission of a Biologics License Application (BLA) for RP1 in combination with nivolumab following FDA communications. This represents a material regulatory development for a clinical-stage biopharmaceutical company, as BLA resubmission decisions directly impact the path to commercialization and investor valuation. While not a traditional earnings release, exec change, or M&A event, the regulatory milestone is material to investors assessing the company's pipeline progress and FDA approval prospects.
View raw filing on EDGAR →The filing discloses a corporate rebranding (name change to "FocalTherics" and ticker change to "FOCL"), combined with a material operational restructuring—the classification of ESWL and Distribution segments as discontinued operations. While the ticker/name change alone might be routine, the discontinued operations announcement signals a significant strategic shift that would materially affect investor assessment of the company's ongoing business and financial trajectory. This combination of rebranding and segment discontinuation does not fit neatly into the more specific event categories and is best classified as other_material.
View raw filing on EDGAR →The disclosure announces Board approval of a quarterly cash dividend payable to shareholders, which is material to investors as it signals capital allocation policy and financial health. However, routine dividend announcements do not fit neatly into the standard 8-K taxonomy categories (earnings_release, exec_departure, etc.), making "other_material" the most appropriate classification for this shareholder-relevant financial event.
View raw filing on EDGAR →The company formed a Special Committee to review strategic alternatives, including financing, recapitalization, equity issuance, asset sales, and debt restructuring, with Houlihan Lokey retained as financial advisor. This broad mandate signals potential material corporate changes that could affect the company's financial condition and strategic direction.
View raw filing on EDGAR →The filing discloses a one-for-eight reverse stock split and reduction in authorized shares from 150,000,000 to 18,750,000, approved by stockholders on May 19, 2026 and effective May 29, 2026. While this is a structural capital event that affects all shareholders proportionately and is material to investors (affecting share count, trading basis, and equity compensation plans), it does not fit neatly into the more specific event categories. Reverse stock splits are typically routine corporate actions undertaken to maintain listing compliance or improve stock price perception, and the disclosure emphasizes no change in percentage ownership or par value. This is classified as other_material rather than a more specific category because the taxonomy lacks a dedicated reverse-split classification.
View raw filing on EDGAR →The Company implemented a 1-for-10 reverse share split effective May 28, 2026, approved by shareholders on May 5, 2026, through an amendment to its Memorandum of Association filed with the Cayman Islands Companies Registry. In connection with this capital restructuring, warrant terms were materially modified, including a reduction in the number of shares issuable per warrant to 1/10th and a ten-fold increase in exercise price to $15,525.00, proportionally adjusting warrant holders' economic rights.
View raw filing on EDGAR →Heritage Insurance announced successful placement of its 2026-2027 catastrophe excess-of-loss reinsurance program for its three insurance subsidiaries. For an insurance holding company, securing reinsurance capacity is material to investors as it directly affects the company's ability to manage catastrophic risk exposure and maintain underwriting capacity. However, the disclosure is routine operational news rather than a discrete event type (M&A, covenant breach, impairment, etc.), warranting classification as other_material.
View raw filing on EDGAR →The fund disclosed Transactional NAV per Unit as of April 30, 2026 (Class I: $29.08, Class S: $28.75, Class D: $28.98) and aggregate fund NAVs ($5.0 billion for BXINFRA, $272.0 million for BXINFRA Lux), establishing the pricing basis for unit transactions and reflecting the fund's asset valuation.
View raw filing on EDGAR →Palomar announced successful completion of reinsurance programs incepting June 1, 2026, including $421 million of incremental earthquake limit and increased full-year 2026 adjusted net income guidance, reflecting expanded reinsurance capacity and improved risk profile.
View raw filing on EDGAR →The filing discloses a declared distribution to shareholders of $0.1560 per share (gross) across three share classes, payable on June 3, 2026. While distribution declarations are routine for REITs and real estate investment trusts, this disclosure under Item 7.01 (Regulation FD Disclosure) rather than a standard earnings release or distribution announcement suggests it may carry material significance to investors assessing dividend sustainability and cash flow. However, the event does not fit cleanly into the more specific taxonomy categories (earnings_release, which typically includes full financial results; or other standard event types), making "other_material" the most appropriate classification.
View raw filing on EDGAR →The filing discloses a distribution declaration for multiple share classes with specific per-share amounts ($0.0423 gross), record and payment dates, and notably waives the stockholder servicing fee on Class D shares in perpetuity. While distribution declarations are routine for REITs, the perpetual waiver of Class D servicing fees is a material change to the fee structure that affects shareholder economics and is not a standard administrative disclosure.
View raw filing on EDGAR →Chase Issuance Trust completed a $1.25 billion securitization of credit card receivables on May 28, 2026, issuing Class A(2026-1) notes as part of the CHASEseries. While this is a significant financing transaction, it does not fit cleanly into the M&A activity category (which typically covers acquisitions, dispositions, mergers, or changes of control) nor any other more specific event type. The disclosure is material to investors as it represents a substantial capital markets transaction and refinancing activity, but the securitization structure and credit risk retention mechanics do not align with standard M&A or dilutive issuance classifications.
View raw filing on EDGAR →The filing discloses a declared distribution of $0.04326 per share (net of fees) across multiple share classes, payable June 10, 2026. While distribution declarations are routine for REITs and typically immaterial administrative disclosures, this Item 7.01 Regulation FD Disclosure suggests the company deemed the distribution announcement material enough to file an 8-K. The specific per-share amounts and payment details would affect investor assessment of yield and cash flow, making it material to shareholders, though it does not fit neatly into the standard event taxonomy.
View raw filing on EDGAR →The Fund disclosed its NAV per Class I share of $25.87 as of April 30, 2026, aggregate NAV of $1,039.0 million, portfolio composition of 171 companies with $2,076.9 million fair value, and leverage metrics of 1.20x debt-to-equity, providing investors with material information on the Fund's financial condition and risk profile.
View raw filing on EDGAR →The filing discloses a monthly distribution declaration for a real estate investment trust (REIT), specifying gross and net per-share amounts ($0.1927 gross, varying net by share class) payable on June 18, 2026. While distribution announcements are routine for REITs, this disclosure under Item 7.01 (Regulation FD) rather than a dedicated Item suggests it may carry material significance to investors assessing the REIT's cash generation and dividend sustainability. However, the taxonomy lacks a specific "dividend_distribution" category, and the event does not fit cleanly into earnings_release (no financial results) or other defined types.
View raw filing on EDGAR →Antares Private Credit Fund declared a regular distribution of $0.1887 per share, payable June 29, 2026, affecting shareholder cash flow expectations.
View raw filing on EDGAR →The fund disclosed key performance metrics including NAV per share of $24.69 as of April 30, 2026, aggregate NAV of $802.8 million, a debt-to-equity ratio of 1.18x, and ongoing offering progress of $817 million raised through May 1, 2026.
View raw filing on EDGAR →The filing discloses a spin-off and separation of First Tracks Biotherapeutics, Inc. from AnaptysBio, with distribution of First Tracks common stock to stockholders. While the Item 7.01 disclosure itself is limited to tax guidance (Form 8937), the underlying transaction—a material corporate separation and dividend distribution—is a significant capital structure event that would materially affect investor assessment. This does not fit neatly into ma_activity (which typically covers acquisitions/mergers rather than spin-offs), so other_material is most appropriate.
View raw filing on EDGAR →The filing discloses a draw of $1.7 million under a $50 million revolving credit facility established on April 21, 2026 with Parkview Holdings One LLC. While Item 2.03 is the appropriate disclosure vehicle for creation of direct financial obligations, this particular event—the first draw under a previously disclosed credit facility—is a routine drawdown rather than a material new obligation event. The material event (the Loan Agreement itself) was disclosed on April 22, 2026; this May 26 draw is administrative follow-through. However, marked material=true because the $50 million facility and its use for general corporate purposes could be significant to investor assessment of the company's liquidity and capital structure.
View raw filing on EDGAR →American Airlines entered into a Twelfth Amendment to its credit agreement on May 29, 2026, refinancing $1,146.8 million in existing term loans and incurring an additional $703.2 million in incremental term loans, totaling $1,850 million in new debt maturing in 2033. This material debt refinancing and incremental borrowing transaction affects the company's capital structure and liquidity.
View raw filing on EDGAR →The disclosure announces a board decision to consider resumption of quarterly dividends and schedule a special meeting for July 29, 2026. While filed under Item 2.02 (Results of Operations and Financial Condition), the substance is a corporate governance/capital allocation announcement rather than a financial results disclosure. Dividend resumption is material to shareholders but does not fit cleanly into earnings_release, exec_compensation, or shareholder_vote_results categories, warranting classification as other_material.
View raw filing on EDGAR →Stockholders approved an amendment to the Company's Certificate of Incorporation at the May 22, 2026 Annual Meeting increasing authorized shares of common stock from 312.3 million to 452.8 million shares and preferred stock from 24.1 million to 34.9 million shares, materially expanding the Company's capacity to issue equity.
View raw filing on EDGAR →The disclosure describes the consummation of Aperture AC's IPO on May 22, 2026, raising $102 million in gross proceeds from the sale of 10.2 million units at $10.00 per unit, plus a concurrent private placement of 311,000 units for $3.11 million. While this is a material capital-raising event affecting the registrant's financial position, it does not fit cleanly into the earnings_release, ma_activity, or dilutive_issuance categories—it is a SPAC IPO with trust account mechanics rather than a traditional equity offering or M&A transaction. Classified as other_material given its significance to a reasonable investor but lack of precise categorical fit.
View raw filing on EDGAR →The Company drew $5,000 thousand under an unsecured promissory note from its sponsor to extend its business combination deadline from May 29, 2026 to June 29, 2026. While this creates a direct financial obligation (Item 2.03), it is a routine extension mechanism for a SPAC that does not fit neatly into the more specific event categories. The disclosure is material because it signals continued inability to close a business combination and reliance on sponsor funding, which affects investor assessment of the Company's prospects.
View raw filing on EDGAR →The 8-K discloses two press releases announcing "business developments" on May 20 and May 27, 2026, along with a "Pre-Paid Purchase" agreement with Streeterville Capital dated May 22, 2026. Without access to the actual press release content, the specific nature of these developments cannot be determined from the Item 8.01 disclosure alone. The reference to a pre-paid purchase agreement suggests potential financing or capital activity, but the exact materiality and event classification depend on the substance of the announcements, which are incorporated by reference but not detailed in the filing excerpt provided.
View raw filing on EDGAR →The company provided a material update on the development program for ATNM-400, a product candidate, disclosed via press release in connection with receipt of a Notice.
View raw filing on EDGAR →Matternet entered into a material definitive agreement, as disclosed under Item 1.01. Without substantive details on the agreement's parties, terms, or business purpose, the specific event classification cannot be determined with confidence.
View raw filing on EDGAR →Matternet made a material modification to the rights of security holders, as disclosed under Item 3.03. The specific nature of the modification (e.g., charter amendment, voting rights change) cannot be determined from the item heading alone.
View raw filing on EDGAR →Matternet experienced a change in shell company status, as disclosed under Item 5.06. This change materially affects the registrant's regulatory classification and investor protections.
View raw filing on EDGAR →WisdomTree disclosed entry into privately negotiated repurchase agreements to buy back approximately $51.9 million in principal amount of its 3.25% Convertible Senior Notes due 2029 for $87.3 million in cash. This is a material capital allocation and debt reduction event that would affect investor assessment of the company's financial position and leverage, but it does not fit cleanly into the more specific event categories (not M&A, not a covenant breach, not a dilutive issuance). The transaction is material and disclosed under Item 8.01 as an "Other Event."
View raw filing on EDGAR →This Item 2.03 disclosure describes the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines, which are joint and several obligations of all eleven Federal Home Loan Banks. While the filing creates direct financial obligations through debt issuance, the prose emphasizes that the Bank has "not made a judgment as to the materiality of any particular consolidated obligation or obligations" and focuses on regulatory framework and reporting methodology rather than a specific material debt event. The disclosure is material to the Bank's operations but does not fit cleanly into the covenant_breach or other specific debt-related categories, as it describes routine consolidated obligation issuance mechanics rather than a triggering financial event.
View raw filing on EDGAR →The disclosure announces new clinical data for Moleculin's lead drug candidate Annamycin presented at ASCO, highlighting a "differentiated cardiac safety profile." This is material clinical trial progress for a biotech company with a lead candidate in development, as it addresses a critical safety concern that could influence investor assessment of the drug's commercial viability and regulatory pathway. However, it does not fit neatly into earnings_release (no financial results), material_litigation, or other more specific categories, making other_material the most appropriate classification.
View raw filing on EDGAR →Monopar disclosed Phase 2 clinical trial results for ALXN1840 (tiomolibdate choline) in Wilson disease patients presented at a major medical conference (EASL 2026). While this represents material clinical progress for a therapeutic candidate, it does not fit neatly into the standard taxonomy categories (not an earnings release, M&A activity, executive change, or financial restatement). Clinical trial results presented at conferences are typically material to investors assessing pipeline value and development progress, warranting classification as other_material.
View raw filing on EDGAR →Classover Holdings, Inc. amended its certificate of incorporation to change its legal name to 'KIDZ AI Inc.' effective May 26, 2026. The corporate name change is a material event affecting investor identification and security trading.
View raw filing on EDGAR →LyondellBasell entered into an Eighth Amendment to its structured accounts receivable facility, extending the term to June 2027 and reducing the maximum available amount from $900 million to $700 million. This amendment materially affects the Company's liquidity and financing structure.
View raw filing on EDGAR →The filing discloses a press release announcing the launch of a 50+ physical qubit neutral-atom quantum computer with targets for thousands of qubits by end of H1 2027. This represents a significant product milestone and technological achievement for a quantum computing company, but does not fit neatly into standard 8-K event categories (not earnings, M&A, executive changes, impairment, litigation, or cybersecurity). The announcement is material to investors assessing the company's progress and competitive position in quantum computing, warranting disclosure under Item 8.01 (Other Events).
View raw filing on EDGAR →The Company disclosed an inadvertent error in its Definitive Proxy Statement filed May 12, 2026, where the record date for the annual meeting was incorrectly stated as May 12, 2026 when the correct date is May 14, 2026. This error affects stockholder voting eligibility and requires filing a revised proxy statement. While not fitting the specific "restatement" category (which applies to financial statements), this is a material disclosure correction that would affect a reasonable investor's ability to participate in the annual meeting vote.
View raw filing on EDGAR →